Published in Medical Letter on the CDC and FDA, November 23rd, 2003
Dr. Steven K. Libutti of the NCI surgery branch will conduct a phase II clinical study to determine the activity of TNFerade, GenVec's lead oncology product candidate, in rectal cancer. TNFerade is currently being developed by GenVec and is in phase II clinical trials for pancreatic and esophageal cancer.
Under the terms of this agreement, GenVec will provide the NCI with clinical supplies of its proprietary TNFerade product candidate for the study....
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.